SOURCE: Active Biotech

February 28, 2011 04:43 ET

Number of shares and votes in Active Biotech

LUND, SWEDEN--(Marketwire - February 28, 2011) -


The number of shares and votes in Active Biotech has changed as a result of the exercise of employee stock options and the private placement with international institutional investors and qualified investors in Sweden.

Today, the last trading day of the month, there are in total 68,582,691 shares and votes in Active Biotech.

Lund, February 28, 2011

Active Biotech AB (publ)

About Active Biotech

Active Biotech AB (NASDAQ OMX NORDIC: ACTI) is a biotechnology company with focus on autoimmune/inflammatory diseases and cancer. Projects in or entering pivotal phase are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, TASQ for prostate cancer and ANYARA for use in cancer targeted therapy, primarily of renal cell cancer. In addition, laquinimod is in Phase II development for Crohn's and Lupus. Further projects in clinical development comprise the two orally administered compounds, 57- 57 for SLE and Systemic Sclerosis as well as RhuDex™ for RA. Please visit www.activebiotech.com for more information.

Active Biotech AB
PO Box 724, SE-220 07 Lund
Sweden
Tel: +46 (0)46-19 20 00
Fax: +46 (0)46-19 11 00

Active Biotech is required under the Securities Markets Act to make the information in this press release public. The information was submitted for publication at 10:30 am CET on February 28, 2011.

Number of shares and votes in Active Biotech: http://hugin.info/1002/R/1492744/428545.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients. The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via Thomson Reuters ONE

[HUG#1492744]

Contact Information

  • For further information, please contact:
    Hans Kolam
    CFO
    Tel: +46 (0)46 19 20 44
    E-mail: Email Contact